GlassScriptPhysician profile
Rayna Traen
NPI 1306265483
$1,150.11
in general payments reported to CMS, 2019-2025
15 companies · $408 in 2025
The $408 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $27.24 · 2021: $123 · 2022: $66.22 · 2023: $208 · 2024: $156 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $257.56 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $191.13 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $116.75 | 2019-2025 | |
| Genzyme Corporation | $105.18 | 2023-2025 | |
| Csl Behring | $78.01 | 2024-2025 | Hizentra, Andembry |
| Pfizer INC. | $61.29 | 2025 | |
| Pharming Healthcare, INC. | $61.00 | 2023-2025 | Ruconest |
| Abbvie INC. | $50.62 | 2022 | |
| Horizon Therapeutics Plc | $48.10 | 2019 | |
| Bio Products Laboratory USA, INC. | $38.73 | 2023 | Coagadex, Gammaplex |
| Genentech USA, INC. | $36.93 | 2022-2023 | Xolair |
| Lilly USA, LLC | $31.59 | 2025 | Ebglyss |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Incyte Corporation | $23.93 | 2025 | Opzelura |
| Amgen INC. | $22.05 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rayna Traen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.